Birch Hill Investment Advisors Decreased By $365,690 Its Merck & Co (MRK) Stake; Pluristem Therapeutics Inc. (PSTI) Had 2 Analysts Last Week

July 17, 2017 - By marketbeat

Birch Hill Investment Advisors Llc decreased Merck & Co Inc (MRK) stake by 1.2% reported in 2016Q4 SEC filing. Birch Hill Investment Advisors Llc sold 6,305 shares as Merck & Co Inc (MRK)’s stock declined 2.46%. The Birch Hill Investment Advisors Llc holds 518,055 shares with $30.50 million value, down from 524,360 last quarter. Merck & Co Inc now has $172.15 billion valuation. The stock declined 0.46% or $0.29 reaching $62.77 per share. About 2.40 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since July 17, 2016 and is uptrending. It has outperformed by 0.16% the S&P500.

Among 2 analysts covering Pluristem Therapeutics (NASDAQ:PSTI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pluristem Therapeutics had 7 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, July 19 by H.C. Wainwright. MLV maintained Pluristem Therapeutics Inc. (NASDAQ:PSTI) on Friday, August 14 with “Buy” rating. Maxim Group maintained Pluristem Therapeutics Inc. (NASDAQ:PSTI) on Tuesday, August 18 with “Buy” rating. The company was upgraded on Monday, June 19 by Maxim Group. The stock has “Hold” rating by Maxim Group on Monday, February 13. The stock has “Buy” rating by Maxim Group on Monday, July 10. As per Tuesday, December 22, the company rating was maintained by Maxim Group. See Pluristem Therapeutics Inc. (NASDAQ:PSTI) latest ratings:

10/07/2017 Broker: Maxim Group Rating: Buy New Target: $2.0000 Maintain
19/06/2017 Broker: Maxim Group Old Rating: Hold New Rating: Buy Upgrade
13/02/2017 Broker: Maxim Group Old Rating: Buy New Rating: Hold Downgrade

Investors sentiment decreased to 0.5 in Q4 2016. Its down 0.50, from 1 in 2016Q3. It dived, as 7 investors sold Pluristem Therapeutics Inc. shares while 7 reduced holdings. 0 funds opened positions while 7 raised stakes. 2.15 million shares or 22.42% less from 2.77 million shares in 2016Q3 were reported. Credit Suisse Ag owns 0% invested in Pluristem Therapeutics Inc. (NASDAQ:PSTI) for 25,700 shares. Northern Trust has 0% invested in Pluristem Therapeutics Inc. (NASDAQ:PSTI) for 15,000 shares. Hightower Advisors Ltd Liability Co, a Illinois-based fund reported 62,200 shares. United Fincl Advisers Lc invested in 10,000 shares. Oppenheimer And owns 127,000 shares. Citadel Advsr stated it has 10,881 shares or 0% of all its holdings. California Employees Retirement reported 181,700 shares. Kcg Inc stated it has 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). 2,518 are held by Morgan Stanley. One Trading L P holds 782 shares or 0% of its portfolio. Citigroup, a New York-based fund reported 1,040 shares. Psagot Investment House Limited owns 50,712 shares. Jane Street Grp Ltd reported 67,034 shares stake. The New York-based Van Eck Assocs has invested 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Jacobs Levy Equity Inc holds 0% of its portfolio in Pluristem Therapeutics Inc. (NASDAQ:PSTI) for 17,193 shares.

About 169,893 shares traded or 17.20% up from the average. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has declined 7.80% since July 17, 2016 and is downtrending. It has underperformed by 24.50% the S&P500.

Pluristem Therapeutics Inc. is a developer of placenta cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The company has market cap of $114.94 million. The Company’s lead indications are critical limb ischemia , recovery after surgery for femoral neck fracture and acute radiation syndrome. It currently has negative earnings. The Company’s activities are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies.

Birch Hill Investment Advisors Llc increased Zimmer Biomet Hldgs Inc (ZMH) stake by 14,477 shares to 292,927 valued at $30.23M in 2016Q4. It also upped Amazon Com Inc (NASDAQ:AMZN) stake by 539 shares and now owns 60,155 shares. Laboratory Corp Amer Hldgs (NYSE:LH) was raised too.

Among 18 analysts covering Merck & Co. Inc. (NYSE:MRK), 13 have Buy rating, 2 Sell and 3 Hold. Therefore 72% are positive. Merck & Co. Inc. had 41 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was downgraded by BMO Capital Markets to “Market Perform” on Monday, July 18. As per Tuesday, November 24, the company rating was initiated by Berenberg. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Overweight” rating by Barclays Capital on Tuesday, December 1. Jefferies downgraded the shares of MRK in report on Monday, December 19 to “Underperform” rating. The stock has “Hold” rating by Berenberg on Thursday, August 27. The firm has “Market Perform” rating by Cowen & Co given on Wednesday, April 12. Jefferies maintained the shares of MRK in report on Tuesday, June 14 with “Hold” rating. Barclays Capital maintained it with “Overweight” rating and $72 target in Friday, September 9 report. The firm has “Sell” rating given on Tuesday, July 4 by BMO Capital Markets. Jefferies maintained Merck & Co., Inc. (NYSE:MRK) on Thursday, August 27 with “Hold” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: